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Reported synonymous substitutions are generally non-pathogenic, and rare pathogenic 
synonymous variants may be disregarded unless there is a high index of suspicion. 
In a case of IL7 receptor deficiency severe combined immunodeficiency (SCID), the 
relevance of a non-reported synonymous variant was only suspected through the use 
of additional in silico computational tools, which focused on the impact of mutations on 
gene splicing. The pathogenic nature of the variant was confirmed using experimental 
validation of the effect on mRNA splicing and IL7 pathway function. This case reinforces 
the need to use additional experimental methods to establish the functional impact of 
specific mutations, in particular for cases such as SCID where prompt diagnosis can 
greatly impact on diagnosis, treatment, and survival.
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INtRoDUCtIoN
We report a 5-month-old male born to non-consanguineous parents who fulfilled clinical and 
immunological parameters for severe combined immunodeficiency (SCID). He was admitted with 
a history of high fever, diarrhea, and oral thrush (Figure 1A). Physical examination revealed failure 
to thrive and diaper candidiasis. Immunophenotyping showed T-cell lymphopenia and normal to 
elevated B and NK cells. The lymphoproliferative response was absent, and serum immunoglobulins 
were very low, leading to the suspicion of T−B+NK+ SCID (Table 1). First, mutations in the IL2RG 
gene were ruled out, and autosomal recessive IL-7R deficiency was suspected. Sanger sequencing of 
the IL7R gene revealed a heterozygous non-synonymous mutation (c.353G>A, p.C118Y) in exon 3 
Abbreviations: ATG, anti-thymocyte globulin; CADD, combined annotation-dependent depletion; GvHD, graft-versus-host 
disease; HSCT, hematopoietic stem cell transplantation; IL-7R, interleukin 7 receptor; NGS, next-generation sequencing; 
PBMCs, peripheral blood mononuclear cells; PHA, phytohemagglutinin; SCID, severe combined immunodeficiency; SS, 
splice site.
FIgURe 1 | Immune evaluation of patient deficient in IL-7R. (a) Two major aphthous oral ulcers (large ulcers greater than 10 mm in diameter) in a 5-month-old 
male, involving the posterior veil of soft palate. (B) Lower CD127 expression on CD3 T-cells of IL-7R-deficient patient compared with a healthy donor. 
(C,D) Significantly lower phosphorylation of STAT5 (phosphoSTAT5, BD biosciences) in response to IL-7 (R&D systems) was observed in T-cells from the patient 
post-HSCT (IL-7 T cell patient) compared with the healthy donor (IL-7 T cell control). An example of phosphorylation of STAT5 with IL-7 in T-cells from the control 
(in purple) vs. phosphorylation of STAT5 with IL-7 in T-cells from the patient post-HSCT (in green). Normal phosphoSTAT5 in response to IL-2 (Roche) was observed 
in the patient (IL-2 T cell patient) and the healthy donor (IL-2 T cell control) (n = 2). Statistical comparison was performed with unpaired Student’s t-tests, with 
significance defined as **P < 0.01; ns: not statistically significant. (e) Impaired IL7R gene expression in CD3 T-cells from IL-7R-deficient patient 1, 2, and 3 years 
post-HSCT (Pt post-HSCT 1, 2, and 3). These results were compared with P2B (IL-7R-deficient patient with complete immune reconstitution after 19 years 
post-HSCT) and 10 healthy children donors. GADPH was used as the endogenous gene control. Triplicate data from one experiment are shown.
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taBLe 1 | Immunological features of the patient.
parameter Normal range pre-HsCt 1 year after HsCt 2 years after HsCt 3 years after HsCt p2B
Lymphocyte count (no./μL) and phenotype (%) 2500–6000 2970 410 1951 1696 1580
t cells
CD3+ (%) 52–88 6 89 38 59 75
CD3+CD127+ (%) 50–85 2 n.d. 26 13 70.6
CD4+ (%) 33–55 3 23 10 20 39
 CD4+CD45RA+CCR7+ (%) 48–72 0 0 11 5.1 22.2
 CD4+CD45RA−CCR7+/− (%) 22–42 99 99 83 94 78
 CD4+CD45RA+CD31+ (%) 44–60 n.d. n.d. 7 4 17.5
CD8+ (%) 17–34 2 70 26 36 35
 CD8+CD45RA+CCR7+ (%) 28–61 0 14 3.5 1.3 46.6
 CD8+CD45RA−CCR7+ (%) 2.9–7 99 84 5.7 6.4 31.6
 CD8+CD45RA−CCR7− (%) 19–35 55.7 85.2 20.1
 CD8+CD45RA+CCR7− (%) 9–34 35.1 7.1 1.7
 CD8+CD57+ (%) 1–20 n.d. n.d. 57.1 68.4 3
B cells
CD19+ (%) 9–28 66 0a 40.7 30.7 15.3
 CD19+CD27+ (%) 12–35 n.d. n.d. 5.8 n.d. 34.8
 CD19+IgD+CD27− (naive) (%) 57–84 n.d. n.d. 90.7 n.d. 56.3
 CD19+IgD+CD27+ (marginal) (%) 4–12 n.d. n.d. 1.6 n.d. 11.1
 CD19+IgD−CD27+ (switched) (%) 7–25 n.d. n.d. 4.2 n.d. 23.5
 CD19+CD21low (%) 3.5–12.5 n.d. n.d. 13.1 n.d. 2.1
NK cells
CD56+CD3− (%) 2–20 23 10 21.2 9.7 6.3
Lymphoproliferation (cpm)
PHA >50,000 690 11,582 38,610 25,404 140,866
Anti-CD3 >20,000 497 4587 332 900 48,956
Anti-CD3 + anti-CD28 >50,000 583 7589 10,348 28,770 153,308
serum immunoglobulins
IgG (mg/dL) 400–1100 232 n.d. 1120 649 1090
IgA (mg/dL) 10–160 <6.67 n.d. 312 341 255
IgM (mg/dL) 50–180 29 n.d. 133 66 61
IgE (IU/mL) 5–165 <5 n.d. 5 n.d. n.d.
aRituximab.
n.d., not determined.
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(Figure 2A). This mutation, inherited from his healthy mother, 
was previously reported in SCID patients (1). No other missense 
and nonsense mutations, as well as insertions and deletions, were 
found in coding exons or exon–intron boundaries in genomic 
DNA. Since the phenotype of the patient clearly pointed to an 
IL-7R deficiency due to the absence of CD127 expression and 
naive CD4 and CD8 T-cells (Table 1; Figure 1B), we revaluated 
the coding sequence of the IL7R gene. Apart from the c.353G>A 
mutation, we only found another heterozygous synonymous 
mutation that affects codon 111 (c.333T>A, p.V111V) (Genbank 
NM_002185.3). This mutation was inherited from his healthy 
father, but its absence from various mutation repositories (dbSNP 
v.146, Human Gene Mutation Database Professional, ClinVar, 
1000 Genomes Project) indicates that it is a rare polymorphism. 
The CADD tool (http://cadd.gs.washington.edu/score), which 
was developed to evaluate the deleteriousness of various muta-
tion types, indicated a low potential impact of this mutation (raw 
score of −0.077; PHRED-like scaled score of 1.906). However, we 
also evaluated the potential functional impact of this mutation 
by evaluating its influence on gene splicing with computational 
tools developed specifically for this purpose (for materials, see 
Supplementary Material). SplicePort and MaxEntScan indicated 
that a cryptic donor splice site just upstream of this mutation 
could be activated, which would result in the truncation of the 
last 49 nucleotides of exon 3. To verify this prediction, we ana-
lyzed the splicing pattern of IL7R mRNA extracted from patient’s 
PBMCs. In agreement with the expectations, the RT-polymerase 
chain reaction (PCR) gel revealed the presence of two bands 
(Figure 2B). Sequencing of RT-PCR products confirmed that the 
larger fragment contained all correctly spliced exons, whereas 
the smaller fragment lacked the last 49 nucleotides of exon 3 
(Figure 2B). This deletion truncation results in a frameshift that 
leads to a premature stop codon at residue 119 (c.330del49) and 
truncation of the protein C-terminus (Figure 2C), indicating loss 
of functional receptors.
Once the IL-7R deficiency was confirmed, the decision to offer 
hematopoietic stem cell transplantation (HSCT) was made. The 
patient received HSCT from an unrelated HLA identical donor at 
the age of 10 months. The conditioning regimen included ATG, 
fludarabine, and melphalan. He achieved full donor chimerism 
2 months after HSCT (Table S1 in Supplementary Material). The 
patient is currently 4 years old and although successfully rescued 
from SCID by HSCT, he has suffered severe complications: 
hepatic graft-versus-host disease (GvHD), severe malnutrition, 
and diarrhea caused by norovirus infection, respiratory infections 
caused by RSV and EBV, steroid-resistant chronic autoimmune 
FIgURe 2 | genetic analysis of IL7R gene.  
(Continued)
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(a) IL7R genomic DNA sequence showing c.333T>A and c.353G>A mutations. (B) Representation of the exon 3 truncation in the paternal mutated allele 
(c.333T>A), in which the last 49 nucleotides of exon 3 are skipped. cDNA was obtained from the IL-7R-deficient patient, and RT-PCR was done using following set 
of primers corresponding to IL7R that amplified a part of exon 2, exon 3, and a part of exon 4 (IL7R-Exon2-F-5′-GACCTGTGCTTTTGAGGACC and IL7R-Exon4-R-
5′-TCATCCTTTTCCTGGCGGTA). RT-PCR gel shows two bands corresponding to maternal allele (360 bp) and the paternal allele (311 bp) that lacked the last 49 
nucleotides of exon 3. Sequencing trace of the IL7R cDNA sequence illustrates the presence of the truncated version, as well as the presence of the maternal allele 
in the non-truncated version of the mature mRNA. (C) Structural analysis of IL7R–IL7 complex was done using the structure prediction of IL7R–IL7 as reference 
PDB code: 3UP1 (2). The C-terminus IL-7R protein that is truncated after residue 119 is colored in gray. Structure image was done with the Pymol software package 
(PyMOL Molecular Graphics System).
FIgURe 2 | Continued
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thrombocytopenia (<10,000/mm3) requiring Rituximab, 
Klebsiella oxytoca, and Enterobacter cloacae sepsis that needed 
vasoactive drugs and pediatric intensive care unit admission. 
Immunological reconstitution of the patient was deficient in the 
T-cell compartment due to reduced recent thymic emigrants, 
decreased naive CD4 and CD8 T-cells with a senescent T-cell phe-
notype, reduced CD127 expression, and impaired proliferation 
to phytohemagglutinin (PHA) stimulation (Table  1). Analysis 
of IL-7 induced pSTAT5 (Y694) in T-cells from the patient was 
also reduced in comparison with healthy donors (Figures 1C,D). 
At molecular level, IL7R mRNA expression in T-cells in samples 
post-HSCT was severely reduced in the patient compared with 
healthy donors (Figure  1E). The immunological findings after 
HSCT of this patient were compared with another IL-7R deficient 
patient (P2B) (3) who experienced complete immune reconstitu-
tion 19 years post-HSCT (Table 1). The protocols of this study 
were approved by the Institutional Review Board of Hospital 
Universitario 12 de Octubre (Madrid, Spain).
MetHoDs
Flow Cytometry
Proportions and lymphocyte count of T-, B-, and NK-cells were 
determined in blood samples using conjugated mouse antihuman 
monoclonal antibodies and analyzed by flow cytometry using a 
Navios Cytometer (Beckman Coulter, Madrid, Spain).
proliferation assay
Heparinized whole blood from the patients were diluted in 
complete medium and cultured with the following mitogens: 
PHA (Sigma, Madrid, Spain), anti-CD3 antibody, and anti-
CD3 +  anti-CD28 antibodies (BDbiosciences, Madrid, Spain). 
The samples were cultured in triplicate wells for 3 days at 37°C in 
a humidified incubator containing 5% CO2, then the wells were 
pulsed individually with 1 μCi of [3H]-thymidine and incubated 
during the last 18 h. The amount of radioactivity was measured 
in a scintillation counter with results expressed as counts per 
minute.
Immunoglobulins
Total serum immunoglobulins (IgG, IgA, IgM, and IgE) were 
measured by nephelometry (Beckman Coulter, Madrid, Spain).
Molecular genetics
Genomic DNA was extracted from EDTA whole blood using a 
MagNa Pure Compact Nucleic Acid Isolation Kit (Roche, Madrid, 
Spain). PCR to amplify the eight exons of IL7R gene, and their 
flanking regions were carried out using specific primers (Primers 
available upon request). Purified PCR products were sequenced 
using an ABI PRISM 3130 genetic analyzer.
gene expression
Total RNA was isolated with the RNeasy plus mini kit (Quiagen, 
Madrid, Spain). One microgram of total cellular RNA was reverse 
transcribed using a Transcriptor First Strand cDNA Synthesis Kit 
(Roche). IL7R gene expression quantification was measured by 
qRT-PCR using a TaqMan probe in a LightCycler 480 instrument 
(Roche) according to the manufacturer’s protocol. GADPH was 
used as the endogenous control, and the level of expression of 
IL7R was quantitatively measured relative to that in 10 different 
donors.
BaCKgRoUND
Severe combined immunodeficiency is a life-threatening disor-
der characterized by profound impairment of both cellular and 
humoral immunity. Patients suffer severe and opportunistic 
infections, protracted diarrhea, and failure to thrive, leading to 
a fatal outcome in their first year of life (4). SCID is a genetically 
heterogeneous disorder caused by mutations in more than 20 
different genes and is classified according to the immunological 
phenotype and the corresponding underlying molecular defect. 
T−B+NK+ SCID phenotype is frequently caused by defects in the 
α chain of the interleukin-7 receptor (IL-7R or also known as 
CD127) (5). More than 50 cases of IL-7R deficiency have been 
described (approximately 10% of SCID cases). A rapid molecular 
screen is essential to distinguish among SCID patients, so they 
undergo early HSCT (6).
DIsCUssIoN
The c.333T>A mutation illustrates the first case of a synony-
mous nucleotide substitution in the coding region of the IL7R 
gene that results in abnormal splicing. We note that, as expected 
for a fourfold degenerate site, the site of this mutation appears 
to have evolved essentially neutrally in the mammalian line-
age as suggested by low, negative phyloP, and GERP++ scores 
(−0.1606 and −1.61, respectively). However, the phyloP score 
computed for the primate lineage (0.505) indicates a high level 
of conservation of this site in primates, which are the only 
species that have a GT dinucleotide (specific for a donor splice 
site) preceding it. Therefore, it is tempting to speculate that 
conservation of this site in primates was maintained to avoid 
taBLe 2 |  In silico analysis of the impact of four synonymous mutations on the strength of neighboring canonical and cryptic donor splice sites using 
four computational tools.
Features/scores Mutation
c.333t>a c.1767C>t c.2961C>t c.333t>C
Tool Gene IL7R JAK3 JAK3 IL7R
Chromsome 5 19 19 5
Genomic coordinate (hg19) 35,867,519 17,947,957 17,942,054 35,867,519
Gene strand + – – +
Reference transcript NM_002185 NM_000215 NM_000215 NM_002185
Exon number 3 13 21 3
Exon size (bps) 158 85 173 158
Distance from donor SS 47 20 18 47
Activated cryptic 5′ SS 35,867,516 17,947,959 17,942,056 35,867,516
SplicePort Canonical 3′ SS 0.652895 0.870339 0.721877 0.652895
Canonical 5′ SS 1.50677 0.446207 −1.01599 1.50677
Cryptic 5′ SS −0.260474 NA NA −0.260474
Mutant canonical 5′ SS 1.03778 0.32365 −1.24002 1.56303
Mutant cryptic 5′ SS 0.588026 0.634022 0.62936 −0.280607
Δ canonical 5′ SS −0.46899 −0.12256 −0.22403 +0.05626
Δ cryptic 5′ SS +0.84850 +0.634022 +0.62936 −0.02013
Human Splicing Finder Canonical 3′ SS 90.75 85.87 88.44 90.75
Canonical 5′ SS 95.68 80.22 83.82 95.68
Cryptic 5′ SS 83.35 57.5 65.81 83.35
Mutant canonical 5′ SS 95.68 80.22 83.82 95.68
Mutant cryptic 5′ SS 88.37 84.33 92.64 83.35
Δ canonical 5′ SS 0 0 0 0
Δ cryptic 5′ SS +6.02 +26.83 +26.83 0
MaxEntScan Canonical 3′ SS 9.26 8.5 9.26 9.26
Canonical 5′ SS 9.14 3.45 3.44 9.14
Cryptic 5′ SS 5.64 -0.78 -0.34 5.64
Mutant canonical 5′ SS 9.14 3.45 3.44 9.14
Mutant cryptic 5′ SS 9.45 6.96 7.41 4.85
Δ canonical 5′ SS 0 0 0 0
Δ cryptic 5′ SS +3.81 +7.74 +7.75 −0.79
NNSPLICE Canonical 3′ SS 0.96 0.81 0.45 0.96
Canonical 5′ SS 1.00 0.06 0.05 1.00
Cryptic 5′ SS 0.25 NA NA 0.25
Mutant canonical 5′ SS 1.00 0.06 0.05 1.00
Mutant cryptic 5′ SS 0.92 0.90 0.79 0.14
Δ canonical 5′ SS 0 0 0 0
Δ cryptic 5′ SS +0.67 +0.90 +0.79 −0.11
(i) The mutation c.333T>C in IL7R is included in this table to illustrate the fact that although it occurs at the same position as the c.333T>A mutation, it is predicted to have an 
opposite effect on neighboring donor splice sites. Specifically, instead of activating the cryptic donor (5′) splice site, it weakens it, and at the same time, it strengthens the canonical 
donor splice site of the exon.
(ii) The coordinate of the activated cryptic 5′ (donor) splice site corresponds to the last exonic nucleotide that precedes the GT consensus dinucleotide. Several putative cryptic 
splice sites were evaluated, but only the one with the highest mutant score is reported here.
∆ canonical 5′ SS in red represents a weakening of the canonical donor splice site of the exon 3.
∆ canonical 5′ SS in green represents a strengthening of the canonical donor splice site of the exon 3.
∆ cryptic 5′ SS in red represents a weakening of a cryptic donor splice site.
∆ cryptic 5′ SS in green represents an activating of a cryptic donor splice site.
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activation of the cryptic donor splice site in a highly conserved 
exon (both donor and acceptor consensus dinucleotides are 
perfectly conserved throughout vertebrates). However, half of 
all 18 fourfold degenerate sites in exon 3 exhibit similar levels 
of high conservation in primates, indicating that other mecha-
nisms might be at play concomitantly. This aspect is reinforced 
by a T>C transition reported at this site (rs199641706) but 
which is not predicted to activate the preceding cryptic splice 
site in a manner similar to c.333T>A (Table 2). Nonetheless, it 
is clear that impact on splicing of this exon can lead to severe 
phenotypes, as illustrated in this study, which supports splicing 
as one of the evolutionary forces that maintains the conserva-
tion of this site.
Synonymous mutations that affect splicing were known for 
decades to cause various disease phenotypes (7). In the case of 
SCID, only two other synonymous mutations were documented, 
despite the increasing number of diagnosed patients by develop-
ing newborn screening programs in Europe and USA (4). Both 
of those mutations are located in the JAK3 gene: c.1767C>T in 
exon 13 (8) and c.2961C>T in exon 21 (9). Similarly to the case 
7Gallego-Bustos et al. Novel Synonymous Mutation in IL-7R Deficiency
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of the IL7R mutation investigated here, the deleterious effect 
of these mutations results from their activating of a cryptic 
donor splice site. Computational predictions of cryptic splice 
site activation can be made with tools such as SplicePort and 
MaxEntScan that can be used for the evaluation of such sce-
narios (Table 2; Figure S1 in Supplementary Material), although 
the process is not fully automated. In contrast, tools that predict 
splicing alteration without specifically evaluating activation of 
cryptic splice sites have little predicting power for mutations like 
the ones described herein (Table S2 in Supplementary Material), 
but they do remain important tools when specific mutations do 
not activate cryptic splice site. Since effect of mutations cannot 
be known a priori, it is always recommended that predictions 
are performed using multiple tools. However, experimental 
validation of computational predictions needs to be performed 
whenever you suspect a splicing defect in order to give the 
appropriate diagnosis.
CoNCLUDINg ReMaRK
We report the first case of an IL7R causal synonymous mutation 
in a male patient with T−B+NK+ SCID phenotype. This mutation 
(c.333T>A), inherited from his healthy father, activates a cryptic 
exonic donor splice site that leads to exon truncation (r.330del49) 
and premature stop codon. It added to a symptomatic missense 
mutation (c.353G>A, p.C118Y) inherited from his healthy 
mother and together render both IL7R copies non-functional. 
This case reinforces the need for researchers to functionally 
evaluate all mutations found in patients. The advent of next-
generation sequencing (NGS) provides to researchers with 
increased genomic coverage, which in turn requires increased 
efforts for mutation screening. The ever-increasing panel of 
ever-improving computational tools can facilitate such efforts of 
functional prioritization, especially in the case of synonymous 
mutations. Nonetheless, detailed functional reports of specific 
mutations in patients, such as our report of a causal synonymous 
mutation in a SCID patient, are ultimately necessary to provide a 
better understanding of functional impact within the context of 
specific disease phenotypes.
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